Abstract
Although neurological manifestations are well described in patients with connective tissue diseases, there is no evidence of increased frequency during pregnancy. Treatment varies with the neurological disorder and the nature of pathogenetic process, with modifications of usual therapies sometimes required during pregnancy. Termination of pregnancy is a consideration only with the more serious vasculitic diseases (i.e., PAN or WG), in patients with cardiac or renal failure, or in patients with severe exacerbations of their systemic disease that is refractory to therapy.
MeSH terms
-
Abortion, Induced
-
Autoantibodies / analysis
-
Connective Tissue Diseases / diagnosis*
-
Connective Tissue Diseases / immunology
-
Connective Tissue Diseases / therapy
-
Female
-
Humans
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / adverse effects
-
Infant, Newborn
-
Nervous System Diseases / diagnosis*
-
Nervous System Diseases / immunology
-
Nervous System Diseases / therapy
-
Neurologic Examination
-
Pregnancy
-
Pregnancy Complications / diagnosis*
-
Pregnancy Complications / immunology
-
Pregnancy Complications / therapy
Substances
-
Autoantibodies
-
Immunosuppressive Agents